• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • MANUFACTURERS
  • HEADHUNTERS
  • PRODUCT SECTIONS
  • COMPANIES

SPINEMarketGroup

Spine Industry News

  • HOME
  • 2025
  • 2024
  • BROCHURES
  • ARTICLES
  • VIDEOS

J&J Trims Executives’ 2012 Bonuses by 10%

March 18, 2013 By SPINEMarketGroup

Johnson & Johnson’s (JNJ) “mixed” performance in 2012 prompted its board to reduce the planned bonus for Chief Executive Alex Gorsky and other senior officers by 10%, the health-care giant disclosed Wednesday.
J&J said the move was part of a shift in its executive compensation policies to more closely link pay to performance. The company has been criticized by some shareholders for the hefty compensation packages paid to Mr. Gorsky’s predecessor, William Weldon, despite a series of problems at the company in recent years.Mr. Gorsky, who became CEO in April 2012 and chairman in December, still received total compensation valued at about $11 million for 2012, up more than 60% from 2011, reflecting his promotion to the company’s top job.However, J&J’s board concluded the company didn’t meet all of its goals for 2012. Among the disappointments: the McNeil Consumer Healthcare unit didn’t return over-the-counter medicines to pharmacy shelves as quickly as expected. The company has recalled several popular medicines, such as Tylenol, in recent years over manufacturing-quality lapses.
“To hold Mr. Gorsky accountable for the company’s 2012 performance, the board reduced his planned bonus for 2012 by 10%,” according to J&J’s annual proxy statement filed Wednesday with the U.S. Securities and Exchange Commission.This resulted in a performance bonus at 90% of the targeted amount for Mr. Gorsky, 52. His final bonus for 2012 amounted to $1.5 million, below the nearly $1.7 million he would have received at 100% of the targeted amount.Performance bonuses for other top executives including Chief Financial Officer Dominic Caruso also were reduced by 10%, J&J said.J&J said the company met or exceeded several goals for 2012, including earnings and cash flow targets, as well as the number of new medicines approved by regulators. J&J also cited the closing of its purchase of medical-device maker Synthes as a success.
But disappointments included 2012 sales growth of 3%–excluding Synthes and foreign exchange–short of the target range of 4% to 5%.
“We had expected to return Consumer products to shelves at a faster rate than we did,” J&J said. “Our reputational standings, while improving in places, are not at the level to which we aspire.”
Other elements of Mr. Gorksy’s compensation included salary of $1.1 million, which was prorated to reflect his appointment to the CEO post in April; $2.8 million in stock awards; and $1.5 million in option awards.Mr. Gorsky’s transition to the role of chairman and CEO in a year with “challenging macro-economic pressures” went “smoothly,” J&J said in the proxy statement. “He generally met expectations of the board, however.. the company’s performance was mixed in 2012 and it was the primary driver of Mr. Gorsky’s assessment.”J&J spokesman Ernie Knewitz said the board modified the executive-compensation policy after listening to feedback from shareholders. In an advisory vote at J&J’s 2012 shareholder meeting, about 57% approved of J&J’s executive compensation program, which J&J deemed to be below satisfactory.Among the changes in J&J’s pay structure, the company no longer targets total direct compensation to a specific percentile of executives at certain peer companies. J&J previously targeted pay between the 50th and 75th percentile of its executive peer group.J&J also dropped tax reimbursements for executive officers that are not provided as part of standard relocation practices.Mr. Weldon plans to officially retire from the company on March 29 after a 41-year career at J&J. He has served as a special adviser to Mr. Gorsky since stepping down from the board in December.Mr. Weldon’s 2012 compensation was valued at $29.8 million, up 11% from 2011, reflecting his service as CEO until April 2012 and as chairman until December.
J&J said it won’t enter any retirement or “golden parachute” agreement with Mr. Weldon. However, Mr. Weldon stands to collect a total of more than $157 million in pension benefits and non-qualified deferred compensation.The deferred compensation of $105.8 million represents portions of Mr. Weldon’s annual salary and bonus from prior years that he elected to defer receiving until retirement.
“He’ll be paid his deferred compensation that’s been built up over years,” Mr. Knewitz said.
Source:Peter Loftus.Dow Jones Newswires

(Visited 30 times, 11 visits today)

Filed Under: NEWS Tagged With: 2013

Primary Sidebar

PLATINUM SPONSORS

GOLD SPONSORS

MOST POPULAR POSTS

  • BROCHURES
  • (UPDATED 2025): 6 Artificial Cervical Discs You’ll…
  • What’s Happening with Globus Medical? Why Has the…
  • Just Reflective, Not Disappointed: Globus Medical’s…
  • (UPDATED 2024): +8 Lumbar Artificial Discs to Know…
  • Stryker’s Spine Business Sale: A Smart Move or a…
  • Stryker’s Spine Exit: What It Means for…
  • Why Didn’t Globus Medical’s Stock Rise After…
  • Globus Medical extends versatility of Advanced…
  • M6 Discontinued: What Are the Alternatives for a…
  • Dispute Over Spinal Implant Royalties Between…
  • Eminent Spine’s 3D Printed Titanium Pedicle Screw…
  • Orthofix Discontinues M6-C™ and M6-L™ Artificial…
  • (Updated!) 15 Expandable PLIF Cages to Know…!
  • (UPDATED 2024): +108 Stand-Alone Cervical Cages to Know..!
  • Alphatec Today: Where It Stands and Where It’s Heading?
  • What Are the Strategic Reasons Behind Globus…
  • Globus Medical Reports First Quarter 2025 Results
  • Update:Stay Tuned Next Week! Is Globus Medical the…
  • Has Globus Already Surpassed Medtronic in the Spine…
  • LAST 10 VIDEOS PUBLISHED

    1. POWEHI MEDICAL AG: TANTO® Screw
    2. Syntropiq: Taurus TLIF (Short)
    3. LEM Surgical: Dynamis Surgical Robot
    4. Aegis Spine:PathLoc-TA
    5. NGMedical: MOVE®-C Artificial Disc
    6. B.Braun Aesculap: Ennovate® Cervical MIS
    7. Spineart: PERLA® TL Deformity Solutions
    8. NGMedical: MOVE®-C
    9. Normmed Medical: ALIF Peek Cage
    10. PainTEQ: LinQ Sacroiliac

    Recent Comments

    • Sandy on Just Reflective, Not Disappointed: Globus Medical’s Bittersweet Q1 2025
    • SPINEMarketGroup on M6 Discontinued: What Are the Alternatives for a Cervical Artificial Disc?
    • Sergio López-Fombona on M6 Discontinued: What Are the Alternatives for a Cervical Artificial Disc?
    • Drew on Has Globus Already Surpassed Medtronic in the Spine Market? Can J&J Find Its Way Back to the Top?
    • Ahmed Hassan El-Naggary on Has Globus Already Surpassed Medtronic in the Spine Market? Can J&J Find Its Way Back to the Top?
    • Anonymous on Has Globus Already Surpassed Medtronic in the Spine Market? Can J&J Find Its Way Back to the Top?
    • Email
    • Twitter
    • YouTube

    Subscribe to Our Newsletter!

    Check your inbox or spam folder to confirm your subscription.

    Footer

    • Email
    • Twitter
    • YouTube

    Contact us:

    [email protected] [email protected]

    PRIVATE POLICY

    • Legal Advice
    • Embed Link
    • VIDEOS

    Copyright © 2025 · SPINEMarketGroup

    Manage Cookie Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
    View preferences
    {title} {title} {title}